Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
The Australasian Journal of Dermatology|September 5, 2020
Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis RegistryBrent J Doolan, Digsu Koye, Joanna Ling, et al.
Multiple Sclerosis and Related Disorders|March 5, 2023
Pain and cognitive performance in adults with multiple sclerosis: A systematic reviewFraser S Brown, Stella A Glasmacher, Daniel Taylor, et al.
The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.
The Australasian Journal of Dermatology|May 20, 2003
Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classificationsLee Mei Yap, Robert Blum, Peter Foley, et al.
Clinical and Experimental Dermatology|February 12, 2022
Method of Assessing Skin Cancerization and Keratoses<sup>TM</sup> (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerizationChristopher Baker, Amelia James, Madeleine Supranowicz, et al.
European Journal of Radiology|March 3, 2009
The role of interventional radiology in obstetric and gynaecology practiceArul Ganeshan, Sarfraz Ahmed Nazir, Lye Quen Hon, et al.
The Australasian Journal of Dermatology|August 8, 2009
Refractory subacute cutaneous lupus erythematosus successfully treated with rituximabViolet Kieu, Timothy O'Brien, Lee-Mei Yap, et al.
Multiple Sclerosis and Related Disorders|May 16, 2022
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosisStella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, et al.
Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
Pageof 24